17 completed. 17 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 17 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Multiple System Atrophy: new trials by email Literature Review of Multiple System Atrophy trials Research Report on Multiple System Atrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy exidavnemab, Placebo Comparator - Parkinson Disease, Multiple System Atrophy | Phase 2 | Completed | BioArctic AB | 38 | 2024-10-24 | 2026-08-21 |
| A Biomarker Study of ATH434 in Participants With MSA ATH434 - Multiple System Atrophy | Phase 2 | Completed | Alterity Therapeutics | 10 | 2023-05-23 | 2025-04-01 |
| A Study of TAK-341 in Treatment of Multiple System Atrophy Placebo, TAK-341 - Multiple System Atrophy | Phase 2 | Completed | Takeda | 158 | 2022-11-16 | 2026-09-24 |
| Study of ATH434 in Participants with Multiple System Atrophy ATH434 dose level 1, ATH434 dose level 2, Placebo - Multiple System Atrophy | Phase 2 | Completed | Alterity Therapeutics | 77 | 2022-07-01 | 2024-12-13 |
| Exenatide Once-weekly as a Treatment for Multiple System Atrophy Exenatide Pen Injector [Bydureon] - Multiple System Atrophy | Phase 2 | Completed | University College, London | 50 | 2020-09-16 | 2025-06-27 |
| Safinamide for Multiple System Atrophy (MSA) Safinamide Methanesulfonate, Safinamide Methanesulfonate matching placebo - Multiple System Atrophy | Phase 2 | Completed | Zambon SpA | 49 | 2019-10-29 | 2021-10-13 |
| Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) NBMI, Placebo - Progressive Supranuclear Palsy, Multiple System Atrophy | Phase 2 | Completed | EmeraMed | 20 | 2019-09-16 | 2021-09-23 |
| Inosine 5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: a Multi-center, Randomized Controlled, Double Blind, Parallel Assigned Clinical Trial 1) Inosine 5'-monophosphate, Placebo - Multiple System Atrophy | Phase 2 | Completed | Yonsei University | 43 | 2018-05-02 | 2019-07-08 |
| Automated Abdominal Binder for Orthostatic Hypotension automated abdominal binder, Sham binder, Placebo - Orthostatic Hypotension, Autonomic Failure | Phase 1 / Phase 2 | Completed | Vanderbilt University Medical Center | 28 | 2018-03-01 | 2026-05-05 |
| TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) TD-9855, Placebo - Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension | Phase 2 | Completed | Theravance Biopharma | 34 | 2017-09-09 | 2022-09-26 |
| AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients AZD3241, Placebo - Multiple System Atrophy, MSA | Phase 2 | Completed | AstraZeneca | 59 | 2015-04-27 | 2017-09-25 |
| Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin. Intranasal Insulin - Parkinson Disease, Multiple System Atrophy | Phase 2 | Completed | Peter Novak | 15 | 2014-02-01 | 2018-11-23 |
| Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA L-Threo DOPS, placebo - Multiple System Atrophy | Phase 2 / Phase 3 | Completed | University Hospital, Toulouse | 107 | 2014-01-21 | 2026-04-08 |
| Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) rasagiline mesylate, placebo - Multiple System Atrophy | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 174 | 2009-12-01 | 2015-02-26 |
| Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins intravenous immunoglobulin (IVIg) - Multiple System Atrophy | Phase 2 | Completed | University of Massachusetts, Worcester | 9 | 2008-06-01 | 2017-02-23 |
| Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy autologous mesenchymal stem cells, normal saline - Multiple System Atrophy | Phase 2 | Completed | Yonsei University | 27 | 2008-05-01 | 2011-08-04 |
| Fluoxetine in Multiple System Atrophy Patients FLUOXETINE - Multiple System Atrophy | Phase 2 | Completed | University Hospital, Toulouse | 87 | 2008-05-01 | 2015-03-26 |
Hypotension, Orthostatic (3) · Parkinson Disease (3) · Thyroid Dyshormonogenesis 2A (3) · Movement Disorders (2) · Neurodegenerative Diseases (2) · Primary Dysautonomias (2) · Pure Autonomic Failure (2) · Shy-Drager Syndrome (2) · Synucleinopathies (2) · Insulin Resistance (1) · Multiple system atrophy (MSA) with orthostatic hypotension (1) · Supranuclear Palsy, Progressive (1)
Autonomic Nervous System Diseases (17) · Basal Ganglia Diseases (17) · Brain Diseases (17) · Central Nervous System Diseases (17) · Nervous System Diseases (17) · Movement Disorders (15) · Neurodegenerative Diseases (15) · Primary Dysautonomias (15) · Synucleinopathies (15) · Cardiovascular Diseases (5) · Hypotension (5) · Vascular Diseases (5) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3) · Orthostatic Intolerance (3)
8-hydroxyquinazolin-4(3H)-one (1) · ATH434 (1) · AZD3241 (1) · Droxidopa (1) · Exenatide (1) · Fluoxetine (1) · Immunoglobulins, Intravenous (1) · Inosine Monophosphate (1) · Insulin (1) · Midodrine (1) · Saline Solution (1) · ampreloxetine (1) · rasagiline (1) · safinamide (1)
Alterity Therapeutics (2) · University Hospital, Toulouse (2) · Yonsei University (2) · AstraZeneca (1) · BioArctic AB (1) · EmeraMed (1) · Peter Novak (1) · Takeda (1) · Teva Branded Pharmaceutical Products R&D, Inc. (1) · Theravance Biopharma (1) · University College, London (1) · University of Massachusetts, Worcester (1) · Vanderbilt University Medical Center (1) · Zambon SpA (1)
United States (9) · France (6) · Italy (5) · United Kingdom (5) · Spain (4) · Austria (3) · Germany (2) · Portugal (2) · South Korea (2) · Australia (1) · Canada (1) · Denmark (1) · Finland (1) · Hungary (1) · Israel (1)
Charlotte Keywood, MD (1) · Italo Biaggioni, MD (1) · Luis E Okamoto, MD (1) · Olivier Rascol, MD (1) · Peter Novak', MD,PhD (1) · Peter Novak, MD, PhD (1) · Tanja Turk, M. Pharm (1) · Werner Poewe, Prof (1)
PMID 23116538, PMID 25498732, PMID 31022213, PMID 33782836, PMID 34657222, PMID 41269291, PMID 41321006
2009 (1), 2018 (1), 2023 (1), R01HL144568 (1)